PATENT COOPERATION TREATY

				WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43 bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet)					
	see form F	PCT/ISA/220							
	ant's or agent's file form PCT/ISA/22			FOR FURTHER See paragraph 2 be					
			International filing date (c27.08.2004	day/month/year)	Priority date (day/month/year) 29.08.2003				
	ational Patent Class _1/19, A23D7/00		both national classification	and IPC					
Applic PUR	eant ATOS N.V.								
1.	This opinion co	ntains indicati	ons relating to the foll	lowing items:					
	☐ Box No. I Basis of the opinion								
	 ☑ Box No. II Priority 								
	Box No. III	•	ment of opinion with rea	ard to novelty, inven	tive step and industrial applicability				
	Box No. IV	Lack of unity of		<u></u>	, , , ,				
	Box No. V	Reasoned stat		s.1(a)(i) with regard t s supporting such st	to novelty, inventive step or industrial atement				
	☑ Box No. VI	Certain docum	ents cited						
	☐ Box No. VII	Certain defect	s in the international app	plication					
	☐ Box No. VIII	Certain observ	ations on the internatio	nal application					
2.	FURTHER ACT	ION							
If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply who the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.									
	If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.								
	For further options, see Form PCT/ISA/220.								
3.	For further details, see notes to Form PCT/ISA/220.								
	ir.,								

Couzy, F

Telephone No. +49 89 2399-7503

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/BE2004/000123

3 FEB 2006

IAP20 Rec'd FOTHE Basis of the opinion Box No. I 1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was field, unless otherwise indicated under this item. This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)). 2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of: a. type of material: a sequence listing table(s) related to the sequence listing b. format of material: in written format in computer readable form c. time of filing/furnishing: Contained in the international application as filed. filed together with the international application in computer readable form. furnished subsequently to this Authority for the purposes of search. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. 4. Additional comments:

· . . .

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/BE2004/000123

	Box	No. II	Priority	
1.	\boxtimes	The foll	lowing document has not been furnished:	
		\boxtimes	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).	
			translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).	
		Consec	quently it has not been possible to consider the validity of the priority claim. This opinion has neless been established on the assumption that the relevant date is the claimed priority date.	
2.		has bee	pinion has been established as if no priority had been claimed due to the fact that the priority claim en found invalid (Rules 43 <i>bis</i> .1 and 64.1). Thus for the purposes of this opinion, the international attendicated above is considered to be the relevant date.	
3.	. Additional observations, if necessary:			

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability							
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:							
	the entire international application,						
\boxtimes	claims Nos. 1-5,7,12						
because:							
	the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):						
\boxtimes	the description, claims or drawings (indicate particular elements below) or said claims Nos. 1-5,7,12 are so unclear that no meaningful opinion could be formed (specify):						
	see separate sheet		•				
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.						
⊠	no international search report has been established for the whole application or for said claims Nos. 1-5,7,12						
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:						
	the written form		has not been furnished				
			does not comply with the standard				
	the computer readable form		has not been furnished				
			does not comply with the standard				
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.						
	See separate sheet for further of	detai	ls				

34.5<u>.</u>

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No:

Claims

8-11,13-15

Inventive step (IS)

Yes: Claims

Claims No:

6,8-11,13-15

Industrial applicability (IA)

Yes: Claims

6, 8-11,13-15

No: Claims

2. Citations and explanations

see separate sheet

Box No. VI Certain documents cited

1. Certain published documents (Rules 43bis.1 and 70.10) and / or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

· 30%

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/BE2004/000123

Re Item III.

IAP20 Ros'd PGT/FTO 13 FEB 2006

The subject-matter of claims 1-5, 7 and 12 is defined in terms of desired characteristics of the claimed composition, without mention of the technical features needed to achieve those results. The lack of clarity in the sense of Art. 6 PCT is such that no search could be carried out on the subject-matter of these claims, and that these can not be examined.

For the purpose of the establishment of the international search report as well as of this written opinion, it had to be considered that the composition of the invention comprises at least the essential ingredients as defined on p.7 line 10-14, namely 20-30% fat, 10-25% sweetener, as well as a stabilizer and an emulsifier.

Re Item V.

- 1 The following documents are referred to in this communication:
- D1: US 2002/119238 A1 (PIRES MURILO HADAD) 29 August 2002 (2002-08-29)
- D2: US-A-6 117 473 (COBOS MARIA DEL PILAR ET AL) 12 September 2000 (2000-09-12)
- D3: US-A-5 962 058 (KONISHI YOSHIHIRO ET AL) 5 October 1999 (1999-10-05)
- D4: US-A-5 336 514 (JONES MALCOLM G ET AL) 9 August 1994 (1994-08-09)
- D5: US 2003/104110 A1 (SIKKING ROB ET AL) 5 June 2003 (2003-06-05)
- D6: US-A-4 808 334 (EZAKI MITSUO ET AL) 28 February 1989 (1989-02-28)
- D7: WO 2004/052114 A (UNILEVER PLC; LEVER HINDUSTAN LTD (IN); UNILEVER V (NL); STAM THEODO) 24 June 2004 (2004-06-24)
- D8: EP-A-1 430 790 (FUJI OIL CO LTD) 23 June 2004 (2004-06-23)

NB: Although not being comprised in the relevant prior art for the purposes of Art. 33 (2) and (3) PCT (R. 64.1 and 64.3 PCT), documents D7 and D8 are cited (R. 70.10 PCT) as they might become relevant in later regional phases in case of non-valid priority. However, these documents do not disclose the claimed subject-matter of the current demand.

2. Novelty and inventive step

Sec

2.1 The subject-matter of claims 8-11 and 13-15 is not new (Art. 33 (2) PCT) in light of D1, which also discloses milk-free, protein-free, stable, mechanically stable in whipped form, whippable oil-in-water emulsions comprising fat, sugar, an emulsifier, which are stabilized by polysaccharides and may be UHT sterilized. As for claim 6, it differs from the compositions of D1 by the precision that the content of trans fatty acids should be less than 2%. This is an obvious modification for the skilled person and therefore can not provide support for an inventive step in the sense of Art. 33 (3) PCT.

Same can also be said about D2 or D3, which anticipate the subject-matter of claims 8-11 and 13-15, but are not compatible with claim 6 as the compositions of D2 are primarily stabilized by gelatin (col.2 li.49-50 and 57-58), and those of D3 include proteins, e.g., under the form of milk powder (see col.5 li.50-59).

- 2.2 The most relevant passages of the above cited documents are those mentionned in the International search Report, to which the reader is referred.
- 2.3 The subject-matter of claims 6, 8-11 and 13-15 is industrially applicable in the sense of Art. 33 (4) PCT.

100